PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Related links
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Mol Cell Cardiol. Author manuscript; available in PMC 2013 March 1.
Published in final edited form as:
PMCID: PMC3294048
NIHMSID: NIHMS339845
Copyright notice and Disclaimer
The role of SIRT3 in mitochondrial homeostasis and cardiac adaptation to hypertrophy and aging
Michael N. Sack
Michael N. Sack, Center for Molecular Medicine, NHLBI, NIH, Bethesda, MD 20892, USA;
Address for correspondence: Michael N. Sack, Bld 10-CRC, Room 5-3150, 10 Center Drive, MSC 1454, Bethesda, MD 20892-1454, sackm/at/nih.gov
Small right arrow pointing to: The publisher's final edited version of this article is available at J Mol Cell Cardiol
Publisher's Disclaimer
Abstract
Although acetyl-modification of protein lysine residues has been recognized for many decades, the appreciation that this post-translational modification is highly prevalent in mitochondria and plays a pivotal regulatory role in mitochondrial function has only become apparent since 2006. The classical biological stressors that modulate mitochondrial protein acetylation include alterations in caloric levels and redox signaling and the major enzyme orchestrating deacetylation is the mitochondrial enriched sirtuin SIRT3. Overall the action of SIRT3 modulates mitochondrial homeostasis and SIRT3 target proteins include mediators of energy metabolism and mitochondrial redox stress adaptive program proteins. Given these effects, it is not surprising that the role of SIRT3 has begun to be implicated in cardiac biology. This review gives a brief overview of sirtuin biology and then focuses on the role of the SIRT3 regulatory program in the control of cardiac hypertrophy and aging.
Keywords: Mitochondria, SIRT3, Cardiac Hypertrophy, MnSOD
The high-density of mitochondria in cardiomyocytes reflect the high energy-demand of the heart to maintain contractile function. The functioning of these mitochondria, are in turn tightly aligned to energy transduction and to the control of calcium and redox stress homeostasis to optimize bioenergetic efficiency of the heart [1]. Accordingly, it is not be surprising that cardiac pathology is associated with the disruption of mitochondrial functioning [2, 3] and that innate adaptive programs’ to ameliorate cardiac pathology incorporate pathways to resist mitochondrial injury and to restore and rejuvenate mitochondrial functioning [4–6]. Emerging evidence suggests that the post-translational modification (PTM) of mitochondrial proteins themselves may play an important role in mitochondrial homeostasis and in mitochondrial adaptation to biomechanical stressors. The regulatory programs controlling these PTM’s are beginning to be explored. In this review, the role of mitochondrial protein deacetylation will be explored as one of these PTM’s. Its role in modifying the function of mitochondrial proteins, the regulatory program underpinning this modification, the consequences of this deacetylation and the identified cardiovascular sequelae will be reviewed.
Lysine-residue acetylation is a reversible PTM controlled by a diverse family of acetyltransferase enzymes. This modification involves the covalent transfer of an acetyl group from acetyl-coenzyme A to the ε-amino group on lysine. The reverse reaction is driven by deacetylase enzymes. Recognition of the dynamic flux and ‘coverage’ of mitochondrial protein undergoing acetylation/deacetylation was initially identified in 2006 during a proteomic screen of mitochondria extracted from liver tissue from mice comparing the fed to fasted state [7]. The acetylated peptides sequenced in that study aligned to proteins involved in all the major mitochondrial metabolic pathways and to proteins that modulated redox stress control [7]. Subsequent investigations have shown that an even a wider spectrum of mitochondrial proteins are substrates for lysine-residue acetylation and moreover, that the distribution of proteins modified in the mitochondria appear to be tissue/organ specific [8, 9]. To begin to understand the functional consequences of this PTM, the regulatory program orchestrating these events are being explored.
2.1. Regulatory proteins controlling lysine-residue acetylation
The original enzymes identified controlling lysine-residue acetylation and deacetylation were histone acetyltransferases (HATs) and histone deacetylases (HDACs). These reside in the nucleus and cytosol and are instrumental in regulating gene transcription. Numerous acetyltransferase (AT) enzymes that modify histones have recently been shown to function as non-histone AT’s. These include the Gcn5-related N-acetyltransferase (GNAT) family such as Gcn5/PCAF and multiple N-acetyltransferase (NAT) proteins, Tat-interactive protein 60 (Tip60) and the p300/CBP (CREB binding protein) family [10–13]. Interestingly, Gcn5 and p300 have both been found to acetylate and inactivate the mitochondrial biogenesis master regulatory coactivator proteins – PGC-1α and β [14–16].
The mammalian deacetylases are grouped according to phylogenic and sequence homology. The mammalian class I and II and IV enzymes predominantly function as HDACs and employ zinc as a cofactor [17]. The sirtuins are designated as class III deacetylases and are NAD+-dependent enzymes. The founding member of the sirtuin enzymes is yeast Sir2, which silences chromatin via deacetylation of histones [18]. Sir2 enzymes have been shown to mediate lifespan extension in yeast, worms and flies and are postulated to function, in part, via the modulation of mitochondrial function [19]. Mammals have 7 sirtuin enzymes designated as SIRT1 through SIRT7 and functionally predominantly as non-histone deacetylases. They have distinct tissue distributions and subcellular localizations which together contribute to their diverse biological and non-histone functions [20]. The mammalian sirtuins are further phylogenetically divided by homology of their amino acid core domain [21]. The mitochondrial enriched SIRT3 clusters with SIRT1 and SIRT2 in subclass I. These three enzymes show closest homology to yeast Sir2 and exhibit the most robust deacetylase activity. The additional mitochondrial enriched sirtuins SIRT4 and SIRT5 are assigned to subclasses II and III, and exhibit weaker ADP-ribosyltransferase and deacetylase activities respectively (Reviewed [22]). Additionally, emerging data shows that SIR5 may function in lysine residue desuccinylation and demalonylation [23]. The functional consequence of these alternate modifications of mitochondrial protein lysine residues has not yet been determined and will not be discussed further in this review. Also, as mitochondrial enriched acetyltransferase enzymes have also not been elucidated, the predominant function of the acetyl-lysine PTM in the mitochondrial has been explored in the context of deacetylation. Of the two active mitochondrial deacetylases SIRT3 has been established as the major enzyme [24, 25] and its targets and the relevant biological consequences of the activity of SIRT3 will be discussed in this review. The only target of SIRT5 functioning as a deacetylase identified to date, is a component of the urea cycle [26], and whether this isoform is relevant to cardiac biology as a deacetylase enzyme, or via its alternate activities has not been established.
2.2. Mediators of sirtuin activation
As sirtuin activity is dependent on NAD+, it is not surprising that sirtuin activation is directly linked to the energetic and redox status of the cell as measured by the ratio of NAD+:NADH, by the absolute levels of NAD+, NADH, and by the NAD+ catabolite nicotinamide [27, 28]. Interestingly, nicotinamide itself inhibits sirtuin activity and nicotinamide-depletion during NAD biosynthesis inversely activates sirtuins [29].
The NAD biochemistry in the context of sirtuin control has recently been review [30]. However, in brief, the NAD salvage pathway using nicotinamide as the precursor is the dominant pathway for NAD synthesis in mammalia. Here two intermediary steps in NAD generation are initiated by the conversion of nicotinamide to nicotinamide mononucleotide (NMN) via the nicotinamide phosphoribosyltransferase (NAMPT) enzyme. Nicotinamide/nicotinic acid mononucleotide adenylyltransferase (NMNAT) then converts NMN to NAD. These biochemical pathways are most well characterized in the nucleus, and are pivotal for the activity of SIRT1 [31]. NAMPT has been identified as the rate-controlling step in NAD biosynthesis in that overexpression of Nampt but not Nmnat increased cellular NAD levels [32]. The investigation into the biology of NAD in the mitochondria has begun to be explored, and the identification of a mitochondrial-enriched NMNAT isoform, i.e. NMNAT3 supports the concept of subcellular compartment specific functioning of NAD biosynthesis [33, 34]. Moreover, mitochondrial NAD+ levels can now be measured by mass spectroscopy and have been used to show that the metabolic stress of fasting increases mitochondrial NAMPT with a concomitant rise in mitochondrial NAD+ levels [35].
2.3. Identified targets of SIRT3
The advancing technology of immuno-affinity peptide capture coupled to mass spectroscopy [7] has enabled the identification of growing numbers of SIRT3 substrates [36]. The functional characterization of these substrates has also been advanced by coupling proteomics to metabolomics to identify ‘roadblocks’ in metabolic pathways which uncover enzymes modified by SIRT3 [37]. The major pathways modulated by SIRT3 activity include the mitochondrial catabolism of substrates for the generation of reducing equivalents and ammonia, the control of the electron transfer chain and multiple pathways in the control of redox stress and the oxidation of reactive aldehydes. An overview of the characterized SIRT3 targets is reviewed here.
As SIRT3 is activated by caloric restriction or fasting, it is not surprising that SIRT3 deacetylates and activated numerous mitochondrial enzymes that facilitate the conversion of acetate to acetyl-CoA for energy production in extra-hepatic tissues and for the generation of ketones in the liver. The respective enzymes activation by SIRT3 deacetylation in modulating these pathways include acetyl-CoA synthetase 2 [38, 39] and 3-hydroxy-3-methylglutaryl CoA synthase 2 [40]. Additional metabolic pathway targets in the mitochondria include glutamate dehydrogenase which facilitates the oxidative deamination of glutamate to alpha-ketoglutarate, and the citric acid cycle enzyme isocitrate dehydrogenase 2 [24, 41]. SIRT3 has also been linked to the activation of fatty-acid β-oxidation with the most robust functional characterization showing SIRT3-dependent activation of long-chain acyl-CoA dehydrogenase [37, 42]. As the final common denominator in energy production from the mitochondrial derived reducing equivalents many investigators have explored whether SIRT3 activates components of the electron transfer chain. SIRT3 activation does increase oxidative phosphorylation [25, 43, 44] and has been shown to deacetylate and activate enzymes in complex I and II of the ETC [43–45] with additional deacetylation of proteins in complex V [41, 46]. An additional metabolic pathway induced by SIRT3 under caloric restricted conditions is the urea cycle to detoxify ammonia during amino acid metabolism. The enzyme identified here is ornithine transcarbamoylase [37], although this pathway is probably not operational in the heart.
Additional programs in the mitochondria have also been shown to be modulated by SIRT3 activation under caloric-restricted conditions. Here, SIRT3 activation results in the deacetylation and inactivation of the mitochondrial ribosomal protein L10 (MRPL10) [47]. This results in an NAD-dependent inhibition of mitochondrial protein synthesis, which could be considered an energy-sparing response under nutrient restricted conditions. A pivotal mitochondrial reactive oxygen species scavenging enzyme MnSOD has also been shown to be activated by SIRT3 mediated deacetylation to reduce levels of superoxide [48–50]. The functional consequences of this ameliorative effects in the heart [51–53], as described in greater detail below, and has been described for other degenerative conditions [54]. Interestingly, the activation of citric acid cycle intermediate isocitrate dehydrogenase 2 by SIRT3 also ameliorates age-associated degeneration but here the beneficial effect was attributed to the increase in reduced glutathione levels [55]. The mitochondrial matrix peptidyl-prolyl isomerase cyclophilin D (Ppif) has also been identified as a substrate for SIRT3 mediated deacetylation [53, 56, 57]. Similarly to MRPL10, the deacetylation of cyclophilin D inhibits its activity. Our understanding of the function of cyclophilin D has expanded in recent years to not only include a role in increasing susceptibility to mitochondrial permeability transition (MPT) [58, 59], but also to the regulation of mitochondrial calcium efflux with the concordant regulation of Ca2+-dependent mitochondrial enzyme activities [60]. An additional, albeit indirect, effect of SIRT3-dependent inactivation of cyclophilin D, is the dissociation of hexokinase II from the mitochondria, which plays a role in SIRT3-induced oxidative phosphorylation [56]. The role of SIRT3 mediated inactivation of cyclophilin D in the heart is described in the cardiac specific section below.
In light of the stress-ameliorative effects assigned to SIRT3 function as discussed, we would expect that SIRT3 displays adaptive effects. However, its role in tolerance against cellular stressors is not completely defined. Under certain conditions, SIRT3 has been shown to be necessary for cell survival under genotoxic stress condition in a NAD+-dependent manner [35] and its overexpression in cardiomyocytes support that it may have anti-apoptotic effects [51]. In contrast, SIRT3 has been found to participate in Bcl-2 and JNK2-mediated apoptosis in several human cancer cell line [61], and Kaempferol, a natural flavonoid, induces apoptosis in K562 and U937 cell lines via activation of SIRT3 [62].
A new function of SIRT3 that extends our understanding of its context specific effects has also recently been uncovered following the identification of mitochondrial aldehyde dehydrogenase 2 (ALDH2) as a deacetylase substrate [36]. Here, the modification by SIRT3 did not alter ALDH2 activity, but rather enabled an allosteric interaction [63] whereby the deacetylated lysine residue facilitated the binding of the reactive metabolite of the xenobiotic acetaminophen to ALDH2. In this context, instead of the absence of SIRT3 giving rise in increased redox stress as described previously [46, 49, 55], the maintenance of ALDH2 acetylation enhanced resistance to acetaminophen induced hepatotoxicity [35]. This mechanism is proposed to function in the enhanced susceptibility to acetaminophen-induced injury under fasting and caloric restricted conditions [64, 65], nutrient states known to promote the activation of sirtuin enzymes.
Taken together these finding shows that SIRT3-dependent deacetylation of mitochondrial proteins function in a target substrate specific manner to: increase protein activity; to inhibit protein function and to modulate allosteric binding of reactive metabolites to SIRT3-substrates. These diverse effects are consistent with the concept that SIRT3 functions to fine-tune multiple metabolic programs in response to caloric and redox stressors [22, 66]. In extra-mitochondrial compartments, deacetylation has been shown to enable ubiquitination of the same lysine residue to modulate protein stability [67] and acetylation has been shown to facilitate protein-protein interactions [68]. Taken together this myriad of effects of the modulation of lysine-residue acetylation is exposing very intriguing biological effects of this PTM. Figure 1 shows a schematic outline the emerging role of acetylation/deacetylation on protein functioning.
Figure 1
Figure 1
Schematic of consequences of SIRT3 mediated lysine-residues deacetylation of mitochondrial proteins. The classic physiologic activators of SIRT3 include caloric restriction and redox signaling. In the cardiovascular system, pressure overload and hypertrophic (more ...)
Despite the role of SIRT3 in modulating mitochondrial function, no cardiac phenotype is discernable in young SIRT3 knockout mice [24, 42]. Nevertheless, numerous biomechanical stressors and aging do uncover the homeostatic role of SIRT3 in cardiac biology. A role of SIRT3 in controlling cardiac function in aging is quite intriguing due to the predominant degenerative contribution to cardiac dysfunction and as polymorphisms in SIRT3 gene are linked to survival in the elderly[69, 70]. In this regard, the Ang II type 1 receptor (AT1A) knockout mouse which display increased life span is also associated with upregulation of SIRT3 expression in the kidney [71]. Biomechanical stressor and age-associated effects of SIRT3 are discussed below, following a brief review of how the regulatory control of SIRT3 is modified in the heart in response to biomechanical and redox stressors.
3.1. NAD biology in the heart
Firstly, levels of Nampt, the rate limiting enzyme in NAD salvage pathway is downregulated in numerous cardiac pathologies including cardiac ischemia and pressure overload [72]. In parallel generation of a cardiac specific transgene driving Nampt expression is protective against ischemia-reperfusion injury, has ameliorative effects on mitochondrial energetics and blunts the extent of apoptosis in the heart [72]. Whether these effects are exclusively due to activation of SIRT1 with indirect mitochondrial effects or whether the induction of Nampt modulates SIRT3 activity was not directly ascertained in that study. Nevertheless, in a separate study where NAD was administered to SIRT1 and SIRT3 deficient mice, anti-hypertrophic effect of NAD was found to be dependent on SIRT3 and not on SIRT1 [73]. The mechanism identified in this latter study shows that the AMPK signaling pathway is activated by NAD-dependent SIRT3 activation.
3.2. Cardiac SIRT3 regulation
The recognition that SIRT3 is modulated during cardiac stressors was initially noted in primary cardiomyocytes exposed to hypertrophic agonists [51]. The induction of SIRT3 levels by these agonists and in response to pressure overload and exercise was confirmed in the murine heart [52, 74]. Although the effects of aging on cardiac SIRT3 levels have not been determined, it has been shown that SIRT3 levels are reduced in the vastus lateralis muscle bed in elderly sedentary individuals compared to young sedentary controls [75]. Additionally, endurance exercise results in the induction of SIRT3 levels [74, 75] and this regulation can overcome the age-associated decline in skeletal muscle SIRT3 levels [75].
3.3. Direct cardiac consequences of SIRT3 manipulation
The SIRT3 targets characterized to date would support that the disruption of SIRT3 may have consequences regarding cardiac functioning. As alluded to earlier, young SIRT3 knockout mice do not have any obvious phenotype and Tong and colleagues suggest that SIRT3 knockout mice have normal treadmill performance [74]. However, in-line with the role of SIRT3 in fine tuning mitochondrial homeostasis, it is beginning to emerge that bioenergetic stressors such as prolonged starvation may uncover the role of SIRT3 in biology [42].
This same concept is becoming evident in the heart, where the overall aging process elucidates that SIRT3 deficiency gives rise to increased cardiac dilatation [53], and where the introduction of pressure overload results in maladaptive cardiac hypertrophy in SIRT3 knockout mice [52, 53]. The mechanisms underpinning these pathologies align with the prior functions attributable to SIRT3 that have been described above, and include the increased propensity to calcium-induced mitochondrial permeability and to the increased generation of reactive oxygen species [52, 53]. The ameliorative role of SIRT3 in modulating these stressors is shown in cardiomyocytes where the overexpression of SIRT3 promotes anti-apoptotic programs [51] and in cardiac-restricted SIRT3 transgenic mice, where excess SIRT3 blunts reactive oxygen species levels and enhances the activity of ROS scavengers including SOD2 and catalase [52].
An interesting additional mechanism whereby SIRT3 deficiency could potentially contribute to the pathophysiology of cardiac hypertrophy is the role of this sirtuin in fat metabolism [42]. As the loss of metabolic plasticity with the downregulation of fatty acid oxidation (FAO) is synonymous with cardiac pressure-overload mediated decompensation [76, 77], it is feasible that the downregulation of FAO in SIRT3 knockout mice may play a role in the pressure-overload and aging maladaptive phenotype in the heart. This concept has not been explored and warrants direct investigation. Figure 2 shows the identified and potential roles’ whereby SIRT3 functions to modulate cardiac adaptation to pressure overload.
Figure 2
Figure 2
The established role of SIRT3 in the heart. SIRT3 activation in response to hypertrophic signaling increases the activity of MnSOD and inhibits cyclophilin D. SIRT3 has also been shown to increase fatty acid oxidation in the heart with increased LCAD (more ...)
4. Conclusions
Our understanding of the biology of SIRT3 mediated modulation of mitochondrial homeostasis has blossomed over the last 5 years. During this time numerous targets of SIRT3 deacetylation have been identified and uncover the wide array of mitochondrial pathways regulated by the activity of this sirtuin. The bulk of emerging evidence shows that SIRT3 plays an adaptive role in mitochondrial and cellular homeostasis including in the heart. The pursuit of sirtuin agonists continues [78] and their role in cardiac pathology may prove to be a fruitful avenue for future cardiac therapeutics.
​
Highlights
  • SIRT3 is a mitochondrial enriched protein lysine residue deacetylase
  • Deacetylation of mitochondrial proteins modifies target protein function
  • SIRT3 target proteins control mitochondrial energetics and ROS levels
  • SIRT3 ameliorates pressure-overload and aging associated cardiac dysfunction
Acknowledgments
MNS is funded by the Division of Intramural Research of the NHLBI, NIH.
Abbreviations
ALDH2aldehyde dehydrogenase 2
AMPKadenosine monophosphate kinase
CREBcyclic AMP response element binding protein
GNATGcn5-related N-acetyltransferase
HAThistone acetyltransferase
HDAChistone deacetylase
LCADlong chain acetyl-CoA dehydrogenase
MnSODmanganese superoxide dismutase
MPTmitochondrial permeability transition
NADnicotinamide adenine dinucleotide
NAMPTnicotinamide phosphoribosyltransferase
NMNnicotinamide mononucleotide
NMNATNMN adenyltransferase
PTMpost translational modification
PGC-1peroxisome proliferator activated receptor gamma coactivator 1
ROSreactive oxygen species
TCAtricarboxylic acid
Tip60Tat-interactive protein 60

Footnotes
Conflicts: None
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Reference List
1. Johnson DT, Harris RA, Blair PV, Balaban RS. Functional consequences of mitochondrial proteome heterogeneity. Am J Physiol Cell Physiol. 2007 Feb;292(2):C698–707. [PubMed]
2. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005 Mar;115(3):547–55. [PMC free article] [PubMed]
3. Sack MN. Type 2 diabetes, mitochondrial biology and the heart. J Mol Cell Cardiol. 2009;46(6):842–9. [PMC free article] [PubMed]
4. Sack MN. Mitochondrial depolarization and the role of uncoupling proteins in ischemia tolerance. Cardiovasc Res. 2006;72(2):210–9. [PubMed]
5. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88(2):581–609. [PMC free article] [PubMed]
6. Huang C, Andres AM, Ratliff EP, Hernandez G, Lee P, Gottlieb RA. Preconditioning Involves Selective Mitophagy Mediated by Parkin and p62/SQSTM1. PLoS One. 2011;6(6):e20975. [PMC free article] [PubMed]
7. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006;23(4):607–18. [PubMed]
8. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, et al. Regulation of cellular metabolism by protein lysine acetylation. Science. 2010;327(5968):1000–4. [PMC free article] [PubMed]
9. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–40. [PubMed]
10. Kleff S, Andrulis ED, Anderson CW, Sternglanz R. Identification of a gene encoding a yeast histone H4 acetyltransferase. J Biol Chem. 1995;270(42):24674–7. [PubMed]
11. Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY, et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell. 1996;84(6):843–51. [PubMed]
12. Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene. 2007;26(37):5395–407. [PubMed]
13. Eckner R. p300 and CBP as transcriptional regulators and targets of oncogenic events. Biol Chem. 1996;377(11):685–8. [PubMed]
14. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha} J Biol Chem. 2005;280(16):16456–60. [PubMed]
15. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. Cell Metab. 2006;3(6):429–38. [PubMed]
16. Kelly TJ, Lerin C, Haas W, Gygi SP, Puigserver P. GCN5-mediated transcriptional control of the metabolic coactivator PGC-1beta through lysine acetylation. J Biol Chem. 2009 [PubMed]
17. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310–8. [PubMed]
18. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417–35. [PubMed]
19. Guarente L. Mitochondria--a nexus for aging, calorie restriction, and sirtuins? Cell. 2008;132(2):171–6. [PMC free article] [PubMed]
20. Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008;7(2):104–12. [PubMed]
21. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000;273(2):793–8. [PubMed]
22. Bao J, Sack MN. Protein deacetylation by sirtuins: delineating a post-translational regulatory program responsive to nutrient and redox stressors. Cell Mol Life Sci. 2010 Sep;67(18):3073–87. [PMC free article] [PubMed]
23. Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics. 2011 Sep 9; [PubMed]
24. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807–14. [PMC free article] [PubMed]
25. Bao J, Lu Z, Joseph JJ, Carabenciov D, Dimond CC, Pang L, et al. Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms. J Cell Biochem. 2010;110(1):238–47. [PMC free article] [PubMed]
26. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell. 2009;137(3):560–70. [PMC free article] [PubMed]
27. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science. 2000;289(5487):2126–8. [PubMed]
28. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Cohen H, Lin SS, et al. Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels. J Biol Chem. 2002;277(21):18881–90. [PubMed]
29. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem. 2002;277(47):45099–107. [PubMed]
30. Lu Z, Scott I, Webster BR, Sack MN. The emerging characterization of lysine residue deacetylation on the modulation of mitochondrial function and cardiovascular biology. Circ Res. 2009;105(9):830–41. [PMC free article] [PubMed]
31. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–63. [PubMed]
32. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol. 2007;23(2):164–70. [PubMed]
33. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem. 2005;280(43):36334–41. [PubMed]
34. Nikiforov A, Dolle C, Niere M, Ziegler M. Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells: FROM ENTRY OF EXTRACELLULAR PRECURSORS TO MITOCHONDRIAL NAD GENERATION. J Biol Chem. 2011 Jun 17;286(24):21767–78. [PubMed]
35. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130(6):1095–107. [PMC free article] [PubMed]
36. Lu Z, Bourdi M, Li JH, Aponte AM, Chen Y, Lombard DB, et al. SIRT3-dependent deacetylation exacerbates acetaminophen hepatotoxicity. EMBO Rep. 2011 Aug;12(8):840–6. [PubMed]
37. Hallows WC, Yu W, Smith BC, Devires MK, Ellinger JJ, Someya S, et al. Sirt3 Promotes the Urea Cycle and Fatty Acid Oxidation during Dietary Restriction. Mol Cell. 2011 Jan 21;41(2):139–49. [PMC free article] [PubMed]
38. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci USA. 2006;103(27):10230–5. [PubMed]
39. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci USA. 2006;103(27):10224–9. [PubMed]
40. Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab. 2010 Dec 1;12(6):654–61. [PMC free article] [PubMed]
41. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol. 2008;382(3):790–801. [PubMed]
42. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–5. [PMC free article] [PubMed]
43. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA. 2008;105(38):14447–52. [PubMed]
44. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry. 2010;49(2):304–11. [PMC free article] [PubMed]
45. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011 Jan 14;433(3):505–14. [PMC free article] [PubMed]
46. Bao J, Scott I, Lu Z, Pang L, Dimond CC, Gius D, et al. SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic Biol Med. 2010;49:1230–7. [PMC free article] [PubMed]
47. Yang Y, Cimen H, Han MJ, Shi T, Deng JH, Koc H, et al. NAD<+>-dependent deacetylase SIRT3 regulates mitochondrial protein synthesis by deacetylation of the ribosomal protein MRPL10. J Biol Chem. 2009 [PubMed]
48. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010 Dec 1;12(6):662–7. [PubMed]
49. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010 Dec 22;40(6):893–904. [PMC free article] [PubMed]
50. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, et al. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. 2011 May 13; [PMC free article] [PubMed]
51. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol. 2008;28(20):6384–401. [PMC free article] [PubMed]
52. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119(9):2758–71. [PMC free article] [PubMed]
53. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) 2010 Dec;2(12):914–23. [PMC free article] [PubMed]
54. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17(1):41–52. [PubMed]
55. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010 Nov 24;143(5):802–12. [PMC free article] [PubMed]
56. Shulga N, Wilson-Smith R, Pastorino JG. Sirtuin-3 deacetylation of cyclophilin D induces dissociation of hexokinase II from the mitochondria. J Cell Sci. 2010 Mar 15;123(Pt 6):894–902. [PubMed]
57. Shulga N, Pastorino JG. Ethanol sensitizes mitochondria to the permeability transition by inhibiting deacetylation of cyclophilin-D mediated by sirtuin-3. J Cell Sci. 2010 Dec 1;123(Pt 23):4117–27. [PubMed]
58. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005 Mar 31;434(7033):652–8. [PubMed]
59. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005 Mar 31;434(7033):658–62. [PubMed]
60. Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, et al. Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest. 2010 Oct 1;120(10):3680–7. [PMC free article] [PubMed]
61. Allison SJ, Milner J. SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle. 2007;6(21):2669–77. [PubMed]
62. Marfe G, Tafani M, Indelicato M, Sinibaldi-Salimei P, Reali V, Pucci B, et al. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem. 2009;106(4):643–50. [PubMed]
63. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell. 2008;31(4):449–61. [PMC free article] [PubMed]
64. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994 Dec 21;272(23):1845–50. [PubMed]
65. Fernando WK, Ariyananda PL. Paracetamol poisoning below toxic level causing liver damage in a fasting adult. Ceylon Med J. 2009 Mar;54(1):16–7. [PubMed]
66. Sack MN. Caloric excess or restriction mediated modulation of metabolic enzyme acetylation - proposed effects on cardiac growth and function. Biochim Biophys Acta. 2011 Feb 2; [PMC free article] [PubMed]
67. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell. 2007;28(1):91–106. [PubMed]
68. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, et al. Acetylation Targets the M2 Isoform of Pyruvate Kinase for Degradation through Chaperone-Mediated Autophagy and Promotes Tumor Growth. Mol Cell. 2011 Jun 24;42(6):719–30. [PubMed]
69. Bellizzi D, Rose G, Cavalcante P, Covello G, Dato S, De RF, et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics. 2005;85(2):258–63. [PubMed]
70. Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol. 2003;38(10):1065–70. [PubMed]
71. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119(3):524–30. [PMC free article] [PubMed]
72. Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009;105(5):481–91. [PMC free article] [PubMed]
73. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMPK pathway. J Biol Chem. 2009 [PubMed]
74. Palacios OM, Carmona JJ, Michan S, Chen KY, Manabe Y, Ward JL, 3rd, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY) 2009 Sep;1(9):771–83. [PMC free article] [PubMed]
75. Lanza IR, Short DK, Short KR, Raghavakaimal S, Basu R, Joyner MJ, et al. Endurance exercise as a countermeasure for aging. Diabetes. 2008;57(11):2933–42. [PMC free article] [PubMed]
76. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94(11):2837–42. [PubMed]
77. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010 Jan;90(1):207–58. [PubMed]
78. Milne JC, Denu JM. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol. 2008 Feb;12(1):11–7. [PubMed]